ImmunityBio, Inc. (IBRX) DCF Valuation

ImmunityBio, Inc. (IBRX) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

ImmunityBio, Inc. (IBRX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

As an investor or analyst, this [Symbol] DCF Calculator is your go-to resource for accurate valuation. Loaded with real data from ImmunityBio, Inc., you can easily adjust forecasts and observe the effects in real-time.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 2.2 .6 .9 .2 .6 .6 .6 .7 .7 .7
Revenue Growth, % 0 -72.52 54.38 -74.3 159.17 1.89 1.89 1.89 1.89 1.89
EBITDA -142.3 -187.9 -315.4 -335.5 -436.2 -.6 -.6 -.7 -.7 -.7
EBITDA, % -6461.13 -31063.47 -33766.6 -139796.25 -70125.72 -100 -100 -100 -100 -100
Depreciation 9.0 9.1 19.1 24.2 18.5 .6 .6 .7 .7 .7
Depreciation, % 409.26 1511.9 2047.32 10080 2976.21 100 100 100 100 100
EBIT -151.3 -197.1 -334.5 -359.7 -454.7 -.6 -.6 -.7 -.7 -.7
EBIT, % -6870.39 -32575.37 -35813.92 -149876.25 -73101.93 -100 -100 -100 -100 -100
Total Cash 51.7 96.1 317.1 107.2 266.5 .6 .6 .7 .7 .7
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .3 .0 1.3 1.9 3.2
Account Receivables, % 13.76 0 142.72 787.5 509.32
Inventories .0 .0 .0 26.4 .0 .1 .1 .1 .1 .1
Inventories, % 0 0 0 10980.83 0 20 20 20 20 20
Accounts Payable 1.7 11.5 11.4 21.0 9.2 .6 .6 .6 .6 .7
Accounts Payable, % 79.43 1902.48 1222.48 8756.67 1478.3 95.89 95.89 95.89 95.89 95.89
Capital Expenditure -4.3 -1.7 -33.6 -99.4 -30.6 -.6 -.6 -.7 -.7 -.7
Capital Expenditure, % -194.69 -275.87 -3593.47 -41412.92 -4917.04 -100 -100 -100 -100 -100
Tax Rate, % 0.1192 0.1192 0.1192 0.1192 0.1192 0.1192 0.1192 0.1192 0.1192 0.1192
EBITAT -151.2 -195.5 -334.5 -359.7 -454.2 -.6 -.6 -.7 -.7 -.7
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -145.0 -177.9 -350.4 -452.2 -453.0 -6.6 -.6 -.7 -.7 -.7
WACC, % 9.59 9.55 9.6 9.6 9.59 9.59 9.59 9.59 9.59 9.59
PV UFCF
SUM PV UFCF -7.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -1
Terminal Value -9
Present Terminal Value -6
Enterprise Value -14
Net Debt 461
Equity Value -475
Diluted Shares Outstanding, MM 509
Equity Value Per Share -0.93

What You Will Get

  • Real IBRX Financial Data: Pre-filled with ImmunityBio’s historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See ImmunityBio’s intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Customizable Clinical Parameters: Adjust key inputs such as patient demographics, treatment efficacy, and trial timelines.
  • Instant DCF Valuation: Automatically computes intrinsic value, NPV, and other essential metrics in real-time.
  • High-Precision Accuracy: Leverages ImmunityBio's real-world data for credible valuation results.
  • Seamless Scenario Analysis: Easily explore various assumptions and evaluate their impacts on outcomes.
  • Efficiency Booster: Streamlines the valuation process, removing the need for complex model construction.

How It Works

  • Step 1: Download the prebuilt Excel template featuring ImmunityBio's (IBRX) data.
  • Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see recalculated results, including ImmunityBio's (IBRX) intrinsic value.
  • Step 5: Make well-informed investment choices or create reports based on the outputs.

Why Choose This Calculator for ImmunityBio, Inc. (IBRX)?

  • User-Friendly Interface: Tailored for both novice users and seasoned professionals.
  • Customizable Inputs: Adjust parameters easily to suit your specific analysis needs.
  • Real-Time Feedback: Observe immediate updates to ImmunityBio’s valuation as you modify inputs.
  • Pre-Loaded Data: Comes with ImmunityBio’s actual financial figures for swift evaluations.
  • Endorsed by Experts: Utilized by investors and analysts for making well-informed decisions.

Who Should Use This Product?

  • Healthcare Investors: Make informed decisions with a robust analysis tool tailored for biotech investments.
  • Biotech Analysts: Streamline your workflow with a customizable financial model specific to ImmunityBio, Inc. (IBRX).
  • Consultants: Effortlessly modify the template for client reports or presentations about ImmunityBio, Inc. (IBRX).
  • Biotech Enthusiasts: Expand your knowledge of the biotech sector using real-world examples from ImmunityBio, Inc. (IBRX).
  • Educators and Students: Utilize it as a hands-on learning resource in biotechnology and finance courses.

What the Template Contains

  • Pre-Filled Data: Includes ImmunityBio’s historical financials and projections.
  • Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for computing WACC based on user-defined inputs.
  • Key Financial Ratios: Assess ImmunityBio’s profitability, efficiency, and leverage metrics.
  • Customizable Inputs: Easily modify revenue growth, profit margins, and tax rates.
  • Clear Dashboard: Visuals and tables summarizing essential valuation outcomes.

No products were found matching.